$1.91
Today
as of Sep 4, 16:55 ET
Last 30 days
Recent Press Releases & News
Tvardi Therapeutics to Participate in Upcoming Investor Events
Tvardi: Q2 Earnings Snapshot
Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update
Overview
52-week range
$1.50
$44
1% of range
Avg surprise (last 2)
-54.2%
Avg reaction (last 2)
+0.7%
50% positive
Latest IV / EM
1625%
EM ±253.9% · $3 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.69 | — | — | — | — | financials |
| Fri May 8, 2026 | Mar/2026 | $-0.73 | $-0.65 | -12.3% | +77.3% | -0.7% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.59 | — | — | — | — | financials |
| Thu Aug 14, 2025 | Jun/2025 | $1.00 | $-0.51 | -96.1% | — | — | earnings |
| Tue May 13, 2025 | Mar/2025 | $-3.22 | — | — | — | +2.1% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-2.14 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-2.71 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-20.24 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.52 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.58 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.49 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $3M | — | $3M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-7M | $-7M | — | $-6M | $-9M | $-4M | — | $-6M |
| Net income | $-6M | $-7M | — | $-6M | $4M | $-10M | — | $-6M |
| EPS (diluted) | $-0.69 | $-0.73 | — | $-0.59 | $-1.00 | $-3.72 | — | $-2.14 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $16M | $20M | $21M | $21M | $21M | $34M | $32M | $37M |
| Inventory | — | — | — | — | — | $900,000 | $900,000 | $625,000 |
| Total current assets | $17M | $25M | $32M | $38M | $43M | — | $32M | $48M |
| Total assets | $18M | $26M | $32M | $39M | $44M | $39M | $35M | $51M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $9M | $11M | $11M | $11M | $11M | $47M | $41M | $51M |
| Total equity | $8M | $15M | $21M | $28M | $33M | $-101M | $-91M | $-79M |